StocksFundsScreenerSectorsWatchlists
MDVL

MDVL - MedAvail Holdings, Inc Stock Price, Fair Value and News

0USD0Market Closed
0

MDVL Stock Price

View Fullscreen

MDVL RSI Chart

MDVL Valuation

Market Cap

2.3M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

1.66

EV/EBITDA

1.29

Price/Free Cashflow

-0.07

MDVL Price/Sales (Trailing)

MDVL Profitability

Operating Margin

713.95%

EBT Margin

-770.08%

Return on Equity

-199.6%

Return on Assets

-153.79%

Free Cashflow Yield

-1.4K%

MDVL Fundamentals

MDVL Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

-25.41%

Rev. Growth (Qtr)

-34.68%

MDVL Earnings

Earnings (TTM)

-46.0M

Earnings Growth (Yr)

50.58%

Earnings Growth (Qtr)

66.58%

Breaking Down MDVL Revenue

Last 30 days

-0.7%

Last 90 days

-65.6%

Trailing 12 Months

389.3%

How does MDVL drawdown profile look like?

MDVL Financial Health

Current Ratio

6.51

Debt/Equity

0.07

Debt/Cashflow

-20.97

MDVL Investor Care

Shares Dilution (1Y)

0.84%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20221.8M1.6M1.5M1.4M
202116.6M19.3M17.9M1.9M
20205.0M7.2M14.0M14.0M
2019452.0K518.0K802.0K3.8M
2018433.0K462.0K368.0K360.0K
2017282.0K275.0K396.0K526.0K
2016201.0K243.0K285.0K327.0K
20152.3M1.2M0159.0K
20144.6M5.6M03.3M
20131.2M1.5M2.1M3.3M
2012302.5K505.6K708.7K911.7K
201100099.5K

Tracking the Latest Insider Buys and Sells of MedAvail Holdings, Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 28, 2023
seabaugh ramona
sold
-1,726
5.6971
-303
chief financial officer
Sep 01, 2023
seabaugh ramona
acquired
-
-
680
chief financial officer
Mar 21, 2023
seabaugh ramona
sold
-1,009
0.307
-3,287
chief financial officer
Mar 06, 2023
doerr mark edward
sold
-22,650
0.3112
-72,785
chief executive officer
Mar 03, 2023
doerr mark edward
sold
-6,776
0.3262
-20,773
chief executive officer
Mar 03, 2023
seabaugh ramona
sold
-2,264
0.3366
-6,727
chief financial officer
Mar 01, 2023
doerr mark edward
acquired
-
-
282,259
chief executive officer
Mar 01, 2023
seabaugh ramona
acquired
-
-
28,333
chief financial officer
Jul 01, 2022
redmile group, llc
acquired
8,116,560
1.0625
7,639,120
-
Jul 01, 2022
redmile group, llc
acquired
10,000,000
1.0625
9,411,760
-

1–10 of 24

Which funds bought or sold MDVL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
reduced
-33.25
-64,178
62,999
-%
Feb 14, 2024
Redmile Group, LLC
unchanged
-
-1,141,940
3,052,080
0.11%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
unchanged
-
-25,265
75,127
-%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
unchanged
-
-30,200
89,800
-%
Feb 14, 2024
Alyeska Investment Group, L.P.
reduced
-24.66
-304,395
393,405
-%
Feb 14, 2024
Ally Bridge Group (NY) LLC
unchanged
-
-178,024
529,358
0.32%
Feb 14, 2024
ABG-WTT Global Life Science Capital Partners GP Ltd
new
-
1,349,640
1,349,640
2.63%
Feb 14, 2024
ABG-WTT Global Life Science Capital Partners GP Ltd
sold off
-100
-1,803,530
-
-%

1–10 of 30

Are Funds Buying or Selling MDVL?

Are funds buying MDVL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDVL
No. of Funds

Unveiling MedAvail Holdings, Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
alyeska investment group, l.p.
5.43%
87,618
SC 13G/A
Feb 06, 2024
redmile group, llc
73.0%
2,490,137
SC 13D/A
Jun 21, 2023
redmile group, llc
73.1%
124,507,268
SC 13D/A
Jun 21, 2023
ally bridge group-wtt global life science capital partners, l.p.
34.3%
34,237,606
SC 13D/A
Mar 15, 2023
redmile group, llc
56.5%
59,194,400
SC 13D/A
Mar 15, 2023
ally bridge group-wtt global life science capital partners, l.p.
29.6%
27,419,425
SC 13D/A
Feb 14, 2023
alyeska investment group, l.p.
9.99%
8,004,500
SC 13G
Jul 06, 2022
redmile group, llc
50.7%
46,674,144
SC 13D/A
Apr 06, 2022
ally bridge group-wtt global life science capital partners, l.p.
27.1%
20,601,244
SC 13D/A
Apr 06, 2022
redmile group, llc
41.8%
32,556,498
SC 13D/A

Recent SEC filings of MedAvail Holdings, Inc

View All Filings
Date Filed Form Type Document
Mar 21, 2024
25-NSE
25-NSE
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
8-K
Current Report
Feb 06, 2024
SC 13D/A
13D - Major Acquisition
Feb 06, 2024
4
Insider Trading
Feb 02, 2024
8-K
Current Report
Jan 23, 2024
8-K
Current Report

Peers (Alternatives to MedAvail Holdings, Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
355.4B
85.2B
-8.42% -11.18%
10.11
4.17
6.46% 95.94%
318.5B
60.1B
2.93% 8.79%
872.48
5.3
1.40% -97.49%
146.0B
46.5B
-8.36% -37.64%
-105.17
3.14
42.59% -114.62%
143.2B
28.2B
-3.17% 6.28%
21.32
5.08
7.09% 2.52%
84.8B
27.1B
-10.35% -18.24%
14.97
3.13
-0.60% 23.36%
14.9B
15.8B
-2.56% 43.63%
-25.86
0.94
6.17% 76.47%
MID-CAP
4.1B
4.7B
-2.22% -17.04%
-323.64
0.88
4.58% 90.97%
4.1B
1.7B
-15.21% -18.31%
11.46
2.45
49.61% 324.78%
3.2B
8.8B
-5.60% 16.18%
-5.41
0.37
7.79% -163.11%
1.9B
644.4M
-8.96% -5.30%
13.86
2.96
29.14% 50.51%
SMALL-CAP
1.4B
743.2M
9.58% -25.31%
-4.02
1.91
24.65% 80.36%
22.9M
70.0M
-16.39% -47.35%
-2.23
0.38
-19.54% -109.18%
19.0M
-
-4.27% 58.66%
-1.03
0.22
2882.68% -138.52%
1.1M
19.6M
-49.30% -95.63%
-0.07
0.05
80.00% 43.08%
819.8K
117.6M
-89.85% -87.50%
0
0.01
-0.79% -283.60%

MedAvail Holdings, Inc News

Latest updates
TipRanks2 months ago
Insider Financial24 months ago

MedAvail Holdings, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-34.7%405,000620,0006,040,50011,461,000543,000265,0003,028,5005,792,0005,030,0004,027,0003,100,0007,145,0002,311,0001,412,0003,118,000350,000154,000149,000149,00066,00088,000
Cost Of Revenue-37.5%227,000363,000-19,121,00010,169,000336,000131,000-12,389,0005,606,0004,857,0003,707,0003,346,0002,162,0001,865,0001,432,000-174,00081,000----
Gross Profit--------186,000173,000320,000-246,0004,983,000446,000-20,000611,000176,00073,00088,00052,0007,00026,000
Operating Expenses-12.1%4,632,0005,268,000-10,374,50012,783,0005,327,0005,548,000-11,766,00011,211,00010,636,0009,971,00027,714,0001,045,000921,000985,0001,476,0001,087,0001,239,0001,051,0001,226,000916,0001,060,000
  S&GA Expenses-7.6%122,000132,000-4,125,5002,126,00055,000100,000-4,660,0001,909,0001,613,0001,534,0001,386,000624,000570,000703,0002,325,000339,000337,000275,000137,500128,000235,000
  R&D Expenses-17.6%145,000176,00014,500178,000219,000258,000248,000232,000201,000168,000150,000154,000163,000215,0001,071,500------
EBITDA Margin46.6%-6.01-11.27-11.49-11.33-10.07-12.23-9.60-2.31-1.68-1.71-1.76-2.15-4.07--------
Interest Expenses-13.6%146,000169,000317,000315,000273,000251,000253,000260,00066,0002,000330,000455,000277,000179,000703,00010,000--13,0002,000-
Income Taxes----22,000-24,000-1,0002,000-------------
Earnings Before Taxes-Infinity%-5,496,000-12,206,500-11,806,000-5,393,000-13,022,00010,939,000-11,271,000-10,464,000-9,452,000-12,096,000-2,488,000-6,536,000-5,690,000-18,462,000-921,000-1,175,000--1,189,000-911,000-1,034,000
EBT Margin41.8%-7.70-13.23-13.23-12.83-11.40-13.34-10.51-2.41-1.79-1.84-1.92-2.37-4.40--------
Net Income66.6%-5,791,000-17,330,000-11,070,000-11,806,000-11,718,000-13,022,000-12,626,000-11,273,000-10,464,000-9,452,000-12,096,000-2,488,000-6,536,000-5,690,000-18,462,000-921,000-1,175,000-975,000-65,000-911,000-1,034,000
Net Income Margin11.4%-33.77-38.12-34.96-32.72-29.59-26.55-22.75-2.41-1.79-1.84-1.92-2.37-4.40--------
Free Cashflow16.2%-4,372,000-5,217,000-10,829,000-11,739,000-12,741,000-13,607,000-14,461,000-11,953,000-6,837,000-10,090,000-13,516,000-5,430,000-4,263,000--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-16.3%29,90835,71433,13249,85152,83327,69238,14352,09761,25059,53869,3313,2814,0723,59118,0033,5734,5195,7364,4554,0034,143
  Current Assets-16.9%27,04932,53128,75239,39840,95015,89130,41042,36554,06553,62163,8672,3133,0282,39814,0882,1632,9984,0552,9032,3132,389
    Cash Equivalents-23.6%14,35918,79611,44427,19629,8785,95020,08936,27548,79747,64357,9962,1477,3203,5628,8493961,1582,1973,811459508
  Inventory15.7%10,0658,7018,8176,4015,6205,0884,7904,2533,1713,1192,8171,3681,4741,5704,5941,6251,6771,6861,6761,7411,767
  Net PPE-7.2%7327894386,3706,3666,1758854,6324,3023,7823,79578.0088.0092.002,703129136142149157164
Liabilities-78.2%6,86331,54512,30818,54520,04621,07719,07020,87919,1517,4578,2641,2591,24497721,1641,2081,2651,3351,6341,158417
  Current Liabilities-19.0%4,1565,1345,9417,0568,4509,3677,5059,1348,9246,6697,6138548028317,6751,0481,0931,1501,6341,158417
  Long Term Debt5.5%1,5061,4284,7989,7519,6799,6089,5389,4669,414-----12,476------
    LT Debt, Non Current5.5%1,5061,4284,7989,7519,6799,6089,5389,4669,414-----12,476------
Shareholder's Equity452.8%23,0454,16920,82431,30632,7876,61519,07331,21842,09952,08161,0678.0031,0191,1336982,3653,2544,40130,9472,8453,726
  Retained Earnings-2.3%-262,827-257,000-239,706-228,600-216,800-205,112-192,090-179,464-168,191-157,727-148,275-41,777-40,962-40,191-121,230-38,138-37,217-36,042-35,067-35,002-34,091
  Additional Paid-In Capital0.2%257,318256,847256,308255,642247,598217,249216,685216,204215,700214,125213,62443,78743,77842,79430,82940,49440,46240,43437,88037,84037,810
Shares Outstanding0.3%1,6141,6101,6031,6011,02565865865565168963639.0039.00--------
Float-----63,600---399,200---10,500---13,900---11,300
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations15.4%-4,400-5,200-10,417-11,583-12,400-13,300-14,319-11,684-6,686-9,830-13,307-5,254-4,174-5,899-17,642-769-1,239104-700-780-
  Share Based Compensation-38.3%38161855556561256425736532326014565.0086.0084.0016122.0028.0024340.0030.0042.00
Cashflow From Investing-141.2%-41.00-17.00-377-171-874-852-1,045-856-701-712-202-313-99.00-203-------
Cashflow From Financing-100.1%-17.0012,579-4,9949,73437,252-23.00-796-8.008,54118969,3583948,03181522,7017.002002,0782567311,059

MDVL Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 405$ 543$ 1,025$ 808
Cost of products sold and services:    
Total cost of products sold and services227336590467
Other operating expenses:    
General and administrative4,3655,0539,32510,488
Selling and marketing12255254155
Research and development145219321477
Total operating expense4,6325,3279,90011,120
Operating loss(4,454)(5,120)(9,465)(10,779)
Loss on issuance of warrants00(10,424)0
(Loss) gain from change in fair value of warrant liabilities(896)02,1490
Interest income0011
Interest expense(146)(273)(315)(524)
Loss before income taxes(5,496)(5,393)(18,054)(11,302)
Income tax expense0(24)0(24)
Net loss and comprehensive loss from continued operations(5,496)(5,417)(18,054)(11,326)
Discontinued operations:    
Loss from discontinued operations(295)(6,301)(5,067)(13,414)
Net loss$ (5,791)$ (11,718)$ (23,121)$ (24,740)
Basic and diluted net loss per share:    
Loss from continued operations - basic (in USD per share)[1]$ (3.06)$ (3.91)$ (10.61)$ (11.05)
Loss from continued operations - diluted (in USD per share)[1](3.06)(3.91)(10.61)(11.05)
Loss from discontinued operations - basic (in USD per share)[1](0.16)(4.54)(2.98)(13.09)
Loss from discontinued operations - diluted (in USD per share)[1]$ (0.16)$ (4.54)$ (2.98)$ (13.09)
Weighted average shares outstanding - basic (in shares)[1]1,798,2451,387,1341,702,3601,024,800
Weighted average shares outstanding - diluted (in shares)[1]1,798,2451,387,1341,702,3601,024,800
Hardware and subscription revenue    
Revenue:    
Total revenue$ 127$ 289$ 431$ 454
Cost of products sold and services:    
Total cost of products sold and services131221376301
Service revenue    
Revenue:    
Total revenue278254594354
Cost of products sold and services:    
Total cost of products sold and services$ 96$ 115$ 214$ 166
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

MDVL Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 14,359$ 11,444
Restricted cash676676
Accounts receivable292404
Inventories10,0658,817
Prepaid expenses and other current assets7112,569
Current assets from discontinued operations9464,842
Total current assets27,04928,752
Property, plant and equipment, net732438
Intangible assets, net657451
Right-of-use assets701624
Other assets4030
Long-term assets from discontinued operations7292,837
Total assets29,90833,132
Current liabilities:  
Accounts payable796818
Accrued liabilities462552
Accrued payroll and benefits8321,379
Deferred revenue346152
Current portion of lease obligations208246
Current liabilities from discontinued operations1,5122,794
Total current liabilities4,1565,941
Long-term debt, net1,5064,798
Long-term portion of lease obligations550441
Long-term liabilities from discontinued operations6511,128
Total liabilities6,86312,308
Commitments and contingencies (Note 10)
Stockholders' equity:  
Common shares ($0.001 par value, 300,000,000 shares authorized, 1,613,870 and 1,603,394 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively)[1]22
Warrants35,48011,148
Additional paid-in-capital257,318256,308
Accumulated other comprehensive loss(6,928)(6,928)
Accumulated deficit(262,827)(239,706)
Total stockholders' equity23,04520,824
Total liabilities and stockholders' equity$ 29,908$ 33,132
[1]Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.
MDVL
MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona.
 CEO
 WEBSITEhttps://medavail.com
 INDUSTRYPharmaceuticals
 EMPLOYEES279

MedAvail Holdings, Inc Frequently Asked Questions


What is the ticker symbol for MedAvail Holdings, Inc? What does MDVL stand for in stocks?

MDVL is the stock ticker symbol of MedAvail Holdings, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MedAvail Holdings, Inc (MDVL)?

As of Mon Apr 08 2024, market cap of MedAvail Holdings, Inc is 2.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDVL stock?

You can check MDVL's fair value in chart for subscribers.

What is the fair value of MDVL stock?

You can check MDVL's fair value in chart for subscribers. The fair value of MedAvail Holdings, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MedAvail Holdings, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDVL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MedAvail Holdings, Inc a good stock to buy?

The fair value guage provides a quick view whether MDVL is over valued or under valued. Whether MedAvail Holdings, Inc is cheap or expensive depends on the assumptions which impact MedAvail Holdings, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDVL.

What is MedAvail Holdings, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 08 2024, MDVL's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 1.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDVL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MedAvail Holdings, Inc's stock?

In the past 10 years, MedAvail Holdings, Inc has provided -0.377 (multiply by 100 for percentage) rate of return.